Table of Contents
Thrombosis
Volume 2012, Article ID 594986, 10 pages
http://dx.doi.org/10.1155/2012/594986
Review Article

Factor V Leiden and Inflammation

1Servicio de Hemoterapia y Hemostasia, Hospital Clínic, C/Villarroel 170, 08036 Barcelona, Spain
2Molecular Imaging Program, National Cancer Institute, 10 Center Drive, Building 10, Room B3B85, Bethesda, MD 20892, USA

Received 5 January 2012; Accepted 6 February 2012

Academic Editor: Nejat Akar

Copyright © 2012 Silvia Perez-Pujol et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Rosing and G. Tans, “Coagulation factor V: an old star shines again,” Thrombosis and Haemostasis, vol. 78, no. 1, pp. 427–433, 1997. View at Google Scholar · View at Scopus
  2. L. Alberio, O. Safa, K. J. Clemetson, C. T. Esmon, and G. L. Dale, “Surface expression and functional characterization of α-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin,” Blood, vol. 95, no. 5, pp. 1694–1702, 2000. View at Google Scholar · View at Scopus
  3. W. R. Gould, P. Simioni, J. R. Silveira, D. Tormene, M. Kalafatis, and P. B. Tracy, “Megakaryocytes endocytose and subsequently modify human factor V in vivo to form the entire pool of a unique platelet-derived cofactor,” Journal of Thrombosis and Haemostasis, vol. 3, no. 3, pp. 450–456, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Butenas and K. G. Mann, “Blood coagulation.,” Biochemistry, vol. 67, no. 1, pp. 3–12, 2002. View at Google Scholar · View at Scopus
  5. V. de Stefano and G. Leone, “Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia,” Haematologica, vol. 80, no. 4, pp. 344–356, 1995. View at Google Scholar · View at Scopus
  6. R. M. Bertina, B. P. C. Koeleman, T. Koster et al., “Mutation in blood coagulation factor V associated with resistance to activated protein C,” Nature, vol. 369, no. 6475, pp. 64–67, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. J. R. Meinardi, S. Middeldorp, P. J. de Kam et al., “The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders,” British Journal of Haematology, vol. 116, no. 3, pp. 625–631, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Y. Y. Lee and J. Hirsh, “Diagnosis and treatment of venous thromboembolism,” Annual Review of Medicine, vol. 53, pp. 15–33, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. W. C. Hooper and C. de Staercke, “The relationship between FV Leiden and pulmonary embolism,” Respiratory Research, vol. 3, p. 8, 2002. View at Google Scholar
  10. M. Cushman, “Inherited risk factors for venous thrombosis,” Hematology/The American Society of Hematology: Education Program, pp. 452–457, 2005. View at Google Scholar
  11. N. S. Key, “VTE: a major Public Health Problem comes to the fore (abstract),” American Society of Hematology, 2009.
  12. D. Ginsburg, “Genetic risk factors for arterial thrombosis and inflammation,” Hematology/The American Society of Hematology: Education Program, pp. 442–444, 2005. View at Google Scholar
  13. E. W. Meesters, H. Hansen, H. M. Spronk et al., “The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus,” Blood Coagulation and Fibrinolysis, vol. 18, no. 1, pp. 21–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Cohen, “Cell mediated immunity and the inflammatory system,” Human Pathology, vol. 7, no. 3, pp. 249–264, 1976. View at Google Scholar · View at Scopus
  15. J. W. Semple, J. E. J. Italiano, and J. Freedman, “Platelets and the immune continuum,” Nature Reviews Immunology, vol. 11, pp. 264–274, 2011. View at Google Scholar
  16. G. DeGaetano, “Historical overview of the role of platelets in hemostasis and thrombosis,” Haematologica, vol. 86, no. 4, pp. 349–356, 2001. View at Google Scholar · View at Scopus
  17. J. Hawiger, “Formation and regulation of platelet and fibrin hemostatic plug,” Human Pathology, vol. 18, no. 2, pp. 111–122, 1987. View at Google Scholar · View at Scopus
  18. J. Chen and J. A. López, “Interactions of platelets with subendothelium and endothelium,” Microcirculation, vol. 12, no. 3, pp. 235–246, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. K. Enjeti, L. F. Lincz, F. E. Scorgie, and M. Seldon, “Circulating microparticles are elevated in carriers of Factor v Leiden,” Thrombosis Research, vol. 126, no. 3, pp. 250–253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Hoffman and D. M. Monroe, “A cell-based model of hemostasis,” Thrombosis and Haemostasis, vol. 85, no. 6, pp. 958–965, 2001. View at Google Scholar · View at Scopus
  21. B. Dahlbäck, “Factor V and protein S as cofactors to activated protein C,” Haematologica, vol. 82, no. 1, pp. 91–95, 1997. View at Google Scholar · View at Scopus
  22. M. Kalafatis, M. D. Rand, and K. G. Mann, “The mechanism of inactivation of human factor V and human factor Va by activated protein C,” Journal of Biological Chemistry, vol. 269, no. 50, pp. 31869–31880, 1994. View at Google Scholar · View at Scopus
  23. B. Dahlback, “New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis,” Thrombosis and Haemostasis, vol. 74, no. 1, pp. 139–148, 1995. View at Google Scholar · View at Scopus
  24. B. Dahlbäck, “Resistance to activated protein C caused by the factor V F506Q mutation is a common risk factor for venous thrombosis,” Thrombosis and Haemostasis, vol. 78, no. 1, pp. 483–488, 1997. View at Google Scholar · View at Scopus
  25. M. Christella, L. G. D. Thomassen, E. Castoldi et al., “Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool,” Haematologica, vol. 88, no. 10, pp. 1150–1156, 2003. View at Google Scholar · View at Scopus
  26. F. Bernardi, E. M. Faioni, E. Castoldi et al., “A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype,” Blood, vol. 90, no. 4, pp. 1552–1557, 1997. View at Google Scholar · View at Scopus
  27. B. Dahlback, “Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene,” Haemostasis, vol. 24, no. 2, pp. 139–151, 1994. View at Google Scholar · View at Scopus
  28. B. Zöller, A. Hillarp, E. Berntorp, and B. Dahlbäck, “Activated protein C resistance due to a common factor V gene mutations is a major risk factor for venous thrombosis,” Annual Review of Medicine, vol. 48, pp. 45–58, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Dahlbäck, “Advances in understanding pathogenic mechanisms of thrombophilic disorders,” Blood, vol. 112, no. 1, pp. 19–27, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. P. M. Ridker, J. P. Miletich, C. H. Hennekens, and J. E. Buring, “Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening,” Journal of the American Medical Association, vol. 277, no. 16, pp. 1305–1307, 1997. View at Google Scholar · View at Scopus
  31. V. de Stefano, P. Chiusolo, K. Paciaroni, and G. Leone, “Epidemiology of factor V leiden: clinical implications,” Seminars in Thrombosis and Hemostasis, vol. 24, no. 4, pp. 367–379, 1998. View at Google Scholar · View at Scopus
  32. J. P. Gregg, A. J. Yamane, and W. W. Grody, “Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations,” American Journal of Medical Genetics, vol. 73, no. 3, pp. 334–336, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. F. R. Rosendaal, T. Koster, J. P. Vandenbroucke, and P. H. Reitsma, “High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance),” Blood, vol. 85, no. 6, pp. 1504–1508, 1995. View at Google Scholar · View at Scopus
  34. F. Prüller, R. B. Raggam, V. Posch et al., “Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generation,” Atherosclerosis, vol. 220, no. 1, pp. 215–218, 2012. View at Publisher · View at Google Scholar
  35. J. Emmerich, F. R. Rosendaal, M. Cattaneo et al., “Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls,” Thrombosis and Haemostasis, vol. 86, no. 3, pp. 809–816, 2001. View at Google Scholar
  36. R. Pullmann Jr., M. Škereňová, J. Lukáč et al., “Factor V Leiden and prothrombin G20210A mutations and the risk of atherothrombotic events in systemic lupus erythematosus,” Clinical and Applied Thrombosis/Hemostasis, vol. 10, no. 3, pp. 233–238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. A. P. Reiner, L. A. Lange, N. L. Smith, N. A. Zakai, M. Cushman, and A. R. Folsom, “Common hemostasis and inflammation gene variants and venous thrombosis in older adults from the Cardiovascular Health Study,” Journal of Thrombosis and Haemostasis, vol. 7, no. 9, pp. 1499–1505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Norstrom and G. Escolar, “Natural anticoagulants and thrombophilia,” in Blood and Bone Marrow Pathology, chapter 36, pp. 583–591, 2nd edition, 2011. View at Google Scholar
  39. A. M. Gewirtz, C. Shapiro, Y. M. Shen, R. Boyd, and R. W. Colman, “Cellular and molecular regulation of factor V expression in human megakaryocytes,” Journal of Cellular Physiology, vol. 153, no. 2, pp. 277–287, 1992. View at Publisher · View at Google Scholar · View at Scopus
  40. R. M. Camire, M. Kalafatis, P. Simioni, A. Girolami, and P. B. Tracy, “Platelet-derived factor Va/Va(Leiden) cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C,” Blood, vol. 91, no. 8, pp. 2818–2829, 1998. View at Google Scholar · View at Scopus
  41. M. R. Owens, “The role of platelet microparticles in hemostasis,” Transfusion Medicine Reviews, vol. 8, no. 1, pp. 37–44, 1994. View at Google Scholar · View at Scopus
  42. L. F. Lincz, F. E. Scorgie, A. Enjeti, and M. Seldon, “Variable plasma levels of Factor v Leiden correlate with circulating platelet microparticles in carriers of Factor v Leiden,” Thrombosis Research, vol. 129, no. 2, pp. 192–196, 2012. View at Publisher · View at Google Scholar
  43. D. C. Altieri, “Inflammatory cell participation in coagulation,” Seminars in Cell and Developmental Biology, vol. 6, no. 5, pp. 269–274, 1995. View at Google Scholar · View at Scopus
  44. G. Grignani and A. Maiolo, “Cytokines and hemostasis,” Haematologica, vol. 85, no. 9, pp. 967–972, 2000. View at Google Scholar · View at Scopus
  45. J. A. Lopez, C. Kearon, and A. Y. Y. Lee, “Deep venous thormbosis,” in Hematology/The American Society of Hematology: Education Program, pp. 439–456, 2004. View at Google Scholar
  46. D. D. Wagner, “The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin,” Thrombosis and Haemostasis, vol. 70, no. 1, pp. 105–110, 1993. View at Google Scholar · View at Scopus
  47. D. E. Lorant, M. K. Topham, R. E. Whatley et al., “Inflammatory Roles of P-Selectin,” Journal of Clinical Investigation, vol. 92, pp. 559–570, 1993. View at Google Scholar
  48. R. P. McEver, “P-selectin and PSGL-1: exploiting connections between inflammation and venous thrombosis,” Thrombosis and Haemostasis, vol. 87, no. 3, pp. 364–365, 2002. View at Google Scholar · View at Scopus
  49. S. D. Carson and J. P. Brozna, “The role of tissue factor in the production of thrombin,” Blood Coagulation and Fibrinolysis, vol. 4, no. 2, pp. 281–292, 1993. View at Google Scholar · View at Scopus
  50. S. C. Body, “Platelet activation and interactions with the microvasculature,” Journal of Cardiovascular Pharmacology, vol. 27, no. 1, pp. S13–S25, 1996. View at Google Scholar · View at Scopus
  51. N. Mackman, “Triggers, targets and treatments for thrombosis,” Nature, vol. 451, no. 7181, pp. 914–918, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. K. K. Wu and P. Thiagarajan, “Role of endothelium in thrombosis and hemostasis,” Annual Review of Medicine, vol. 47, pp. 315–331, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. M. H. F. Klinger, “Platelets and inflammation,” Anatomy and Embryology, vol. 196, no. 1, pp. 1–11, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. R. L. Silverstein, “Activation of Vascular Cells by Microparticles and Other Danger Signals Via the CD36 Scavenger Receptor (abstract),” ASH Annual Meeting, SCI-122011, 2011.
  55. L. M. Beaulieu and J. E. Freedman, “Inflammation & the platelet histone trap,” Blood, vol. 118, pp. 1714–1715, 2011. View at Google Scholar
  56. D. Zucker-Franklin, “Clinical significance of platelet microparticles,” Journal of Laboratory and Clinical Medicine, vol. 119, no. 4, pp. 321–322, 1992. View at Google Scholar · View at Scopus
  57. N. S. Key and H. C. Kwaan, “Microparticles in thrombosis and hemostasis,” Seminars in Thrombosis and Hemostasis, vol. 36, no. 8, pp. 805–806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Mackman and A. P. Owens, “Microparticles in hemostasis and thrombosis,” Circulation Research, vol. 13, pp. 10–1284, 2011. View at Google Scholar
  59. I. Del Conde, C. N. Shrimpton, P. Thiagarajan, and J. A. López, “Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation,” Blood, vol. 106, no. 5, pp. 1604–1611, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Østerud, “Tissue factor expression by monocytes: regulation and pathophysiological roles,” Blood Coagulation and Fibrinolysis, vol. 9, no. 1, pp. S9–S14, 1998. View at Google Scholar · View at Scopus
  61. S. Pérez-Pujol, O. Aras, M. Lozano et al., “Stored platelets contain residual amounts of tissue factor: evidence from studies on platelet concentrates stored for prolonged periods,” Transfusion, vol. 45, no. 4, pp. 572–579, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Escolar, I. Lopez-Vilchez, M. Diaz-Ricart, J. G. White, and A. M. Galan, “Internalization of tissue factor by platelets,” Thrombosis Research, vol. 122, no. 1, pp. S37–S41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. B. Salanova, M. Choi, S. Rolle, M. Wellner, F. C. Luft, and R. Kettritz, “β2-integrins and acquired glycoprotein IIb/IIIa (GPIIb/IIIa) receptors cooperate in NF-κB activation of human neutrophils,” Journal of Biological Chemistry, vol. 282, no. 38, pp. 27960–27969, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. W. Jy, W. W. Mao, L. L. Horstman, J. Tao, and Y. S. Ahn, “Platelet microparticles bind, activate and aggregate neutrophils in vitro,” Blood Cells, Molecules, and Diseases, vol. 21, no. 3, pp. 217–231, 1995. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. S. Kaplan and S. P. Jackson, “The role of platelets in atherothrombosis,” in Hematology/The American Society of Hematology: Education Program, pp. 51–61, 2011. View at Google Scholar
  66. A. T. Nurden, “Platelets, inflammation and tissue regeneration,” Thrombosis and Haemostasis, vol. 105, pp. S13–S33, 2011. View at Google Scholar
  67. C. T. Esmon, “Does inflammation contribute to thrombotic events?” Haemostasis, vol. 30, no. 2, pp. 34–40, 2000. View at Google Scholar · View at Scopus
  68. T. Benfield, K. Ejrnaes, K. Juul et al., “Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study,” Critical Care, vol. 14, no. 2, p. R28, 2010. View at Google Scholar · View at Scopus
  69. C. T. Esmon, K. Fukudome, T. Mather et al., “Inflammation, sepsis, and coagulation,” Haematologica, vol. 84, no. 3, pp. 254–259, 1999. View at Google Scholar · View at Scopus
  70. J. J. Hofstra, M. D. Marcel Schouten, and M. Levi, “Thrombophilia and outcome in severe infection and sepsis,” Seminars in Thrombosis and Hemostasis, vol. 33, no. 6, pp. 604–609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Weiler, B. Kerlin, and M. C. Lytle, “Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies,” Critical Care Medicine, vol. 32, no. 5, pp. S233–238, 2004. View at Google Scholar · View at Scopus
  72. J. Texereau, F. Pene, J. D. Chiche, C. Rousseau, and J. P. Mira, “Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis,” Critical Care Medicine, vol. 32, no. 5, pp. S313–319, 2004. View at Google Scholar · View at Scopus
  73. L. W. Brüggemann, S. H. H. F. Schoenmakers, A. P. Groot, P. H. Reitsma, and C. A. Spek, “Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice,” Critical Care Medicine, vol. 34, no. 8, pp. 2201–2206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. A. E. Tsantes, I. Tsangaris, S. Bonovas et al., “The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients,” Blood Coagulation and Fibrinolysis, vol. 21, no. 2, pp. 175–181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. P. G. Lindqvist and B. Dahlbäck, “Carriership of factor V leiden and evolutionary selection advantage,” Current Medicinal Chemistry, vol. 15, no. 15, pp. 1541–1544, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. N. Isma, T. Breslin, B. Lindblad, and P. J. Svensson, “The Factor V Leiden mutation is associated with a higher blood haemoglobin concentration in women below 50 of the Malmö Thrombophilia Study (MATS),” Journal of Thrombosis and Thrombolysis, vol. 28, no. 3, pp. 255–258, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. M. A. Rodger, M. Paidas, C. McLintock et al., “Inherited thrombophilia and pregnancy complications revisited,” Obstetrics and Gynecology, vol. 112, no. 2, pp. 320–324, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Y. L. Zee, R. J. Glynn, S. Cheng, L. Steiner, L. Rose, and P. M. Ridker, “An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism the women's genome health study,” Circulation: Cardiovascular Genetics, vol. 2, no. 1, pp. 57–62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. B. Dahlback, “Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism,” Journal of Clinical Investigation, vol. 94, no. 3, pp. 923–927, 1994. View at Google Scholar · View at Scopus
  80. M. Lozano, G. Escolar, H. P. Schwarz, R. Hernandez, J. Bozzo, and A. Ordinas, “Activted protein C inhibits thrombus formation in a system with flowing blood,” British Journal of Haematology, vol. 95, no. 1, pp. 179–183, 1996. View at Google Scholar · View at Scopus
  81. A. Mizutani, K. Okajima, M. Uchiba, and T. Noguchi, “Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation,” Blood, vol. 95, no. 12, pp. 3781–3787, 2000. View at Google Scholar · View at Scopus
  82. M. Schouten, K. F. van der Sluijs, J. J. T. H. Roelofs, M. Levi, C. Van't Veer, and T. van der Poll, “Factor V Leiden mutation does not affect coagulopathy or outcome in lethal H1N1 influenza,” European Respiratory Journal, vol. 36, no. 6, pp. 1346–1354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. F. M. Campos, B. S. Franklin, A. Teixeira-Carvalho et al., “Augmented plasma microparticles during acute Plasmodium vivax infection,” Malaria Journal, vol. 9, no. 1, article 327, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Mouelhi, H. Mekki, R. Debbeche, M. Salem, and T. Najjar, “Thrombosis in inflammatory bowel disease: mechanisms and risk factors,” Tunisie Medicale, vol. 87, no. 5, pp. 307–310, 2009. View at Google Scholar · View at Scopus
  85. F. Di Fabio, P. Lykoudis, and P. H. Gordon, “Thromboembolism in inflammatory bowel disease: an insidious association requiring a high degree of vigilance,” Seminars in Thrombosis and Hemostasis, vol. 37, no. 3, pp. 220–225, 2011. View at Publisher · View at Google Scholar
  86. C. A. Spek, F. J. W. ten Kate, and A. A. te Velde, “Factor V Leiden and the etiology of inflammatory bowel disease,” Thrombosis and Haemostasis, vol. 98, no. 3, pp. 670–673, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Tsiolakidou and I. E. Koutroubakis, “Thrombosis and inflammatory bowel disease—the role of genetic risk factors,” World Journal of Gastroenterology, vol. 14, no. 28, pp. 4440–4444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. M. M. Maher and S. H. Soloma, “Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease,” Saudi Journal of Gastroenterology, vol. 14, no. 4, pp. 192–197, 2008. View at Google Scholar · View at Scopus
  89. J. Liang, S. Wu, B. Feng et al., “Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis,” Journal of Gastroenterology, vol. 46, no. 10, pp. 1158–1166, 2011. View at Publisher · View at Google Scholar
  90. F. Magro, M. Dinis-Ribeiro, F. M. Araujo et al., “High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease,” European Journal of Gastroenterology and Hepatology, vol. 15, no. 11, pp. 1157–1163, 2003. View at Publisher · View at Google Scholar
  91. G. Barbara, C. Cremon, G. Carini et al., “The immune system in irritable bowel syndrome,” Journal of Neurogastroenterology and Motility, vol. 17, no. 4, pp. 349–359, 2011. View at Publisher · View at Google Scholar
  92. C. E. Collins, M. R. Cahill, A. C. Newland, and D. S. Rampton, “Platelets circulate in an activated state in inflammatory bowel disease,” Gastroenterology, vol. 106, no. 4, pp. 840–845, 1994. View at Google Scholar · View at Scopus
  93. A. Andoh, T. Yoshida, Y. Yagi et al., “Increased aggregation response of platelets in patients with inflammatory bowel disease,” Journal of Gastroenterology, vol. 41, no. 1, pp. 47–54, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Andoh, T. Tsujikawa, K. Hata et al., “Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease,” American Journal of Gastroenterology, vol. 100, no. 9, pp. 2042–2048, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Leonetti, A. Tesse, C. Martinez, A. Bretagne, J. Reimund, and R. Andriantsitohaina, “Increase in circulating microparticles in inflammatory bowel disease patients induces vascular alterations (abstract),” Archives of Cardiovascular Diseases, vol. 102, p. 51, 2009. View at Google Scholar
  96. P. Chamouard, D. Desprez, B. Hugel et al., “Circulating cell-derived microparticles in Crohn's disease,” Digestive Diseases and Sciences, vol. 50, no. 3, pp. 574–580, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. F. R. Rosendaal, “Venous thrombosis: a multicausal disease,” The Lancet, vol. 353, no. 9159, pp. 1167–1173, 1999. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Aznar-Salatti, G. Escolar, A. Cases et al., “Uraemic medium causes endothelial cell dysfunction characterized by an alteration of the properties of its subendothelial matrix,” Nephrology Dialysis Transplantation, vol. 10, no. 12, pp. 2199–2204, 1995. View at Google Scholar · View at Scopus
  99. A. Cases, E. Bragulat, M. Serradell, A. de la Sierra, and G. Escolar, “Endothelial dysfunction in chronic renal failure,” Nefrologia, vol. 23, pp. 42–51, 2003. View at Google Scholar
  100. M. Serradell, M. Díaz-Ricart, A. Cases et al., “Uremic medium causes expression, redistribution and shedding of adhesion molecules in cultured endothelial cells,” Haematologica, vol. 87, no. 10, pp. 1053–1061, 2002. View at Google Scholar · View at Scopus
  101. K. Joop, R. J. Berckmans, R. Nieuwland et al., “Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms,” Thrombosis and Haemostasis, vol. 85, no. 5, pp. 810–820, 2001. View at Google Scholar · View at Scopus
  102. S. Perez-Pujol, P. H. Marker, and N. S. Key, “Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer,” Cytometry Part A, vol. 71, no. 1, pp. 38–45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. I. Laher, “Microparticles have macro effects in sepsis,” Critical Care Medicine, vol. 39, no. 7, pp. 1842–1843, 2011. View at Publisher · View at Google Scholar
  104. M. L. Mastronardi, H. A. Mostefai, F. Meziani, M. C. Martínez, P. Asfar, and R. Andriantsitohaina, “Circulating microparticles from septic shock patients exert differential tissue expression of enzymes related to inflammation and oxidative stress,” Critical Care Medicine, vol. 39, no. 7, pp. 1739–1748, 2011. View at Publisher · View at Google Scholar